Other News

Stereotaxis Announces CFO Transition

ST. LOUIS, Mo., Sept. 16, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial […]

Medicure Announces Launch of New and Improved ReDS™ PRO

WINNIPEG, Sept. 17, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO (“ReDSTM PRO”) system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart […]

Fujifilm Upgrades Next-Generation Synapse Cardiology PACS

First-of-kind solution now in clinical use at North Memorial Health LEXINGTON, Mass., Sept. 17, 2019 /PRNewswire/ — FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Enterprise Imaging and Medical Informatics solutions, has just launched Synapse Cardiology PACS 5.6.1, the company’s next-generation server-side rendering solution to help streamline image review and reporting across cardiovascular modalities. This […]

FDA Awards AnaBios Grant to Further Develop Preclinical Assay Using Human Primary Cardiomyocytes

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).  Funds from the grant will be used to develop a preclinical biomarker to identify the […]

ViVitro Labs Acquires ProtomedLabs

Merger strengthens European service and expands cardiovascular customization capabilities VICTORIA and MARSEILLE, France, Sept. 17, 2019 /PRNewswire/ — ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related consulting services, announces the acquisition of ProtomedLabs SASU, an ISO 17025 accredited medical device testing laboratory based in Marseille France. The companies will merge operations and form […]

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease

First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon in coronary in-stent restenosis granted in Q2 2019 NEW HOPE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a  biomedical innovation […]

Sensible Medical announces ReDS™ Pro, the next generation of market leading lung fluid management technology for heart failure

Non-invasive monitoring technology assists in managing heart failure patients TENAFLY,  N.J., Sept. 14, 2019 /PRNewswire/ — Sensible Medical Innovations today announced the launch of the ReDSTM PRO system. The debut of the new system was at the Heart Failure society of America conference in Philadelphia, PA. ReDSTM PRO is optimized for the Point-of-Care, designed for use in […]

FDA Clears ARTIS icono Family of Angiography Systems From Siemens Healthineers

ARTIS icono biplane system enables wide variety of neuroradiology and abdominal imaging procedures ARTIS icono floor single-plane system permits vascular, interventional cardiology, surgical, and oncology procedures Product family designed to improve lab utilization and interdisciplinary usage   MALVERN, Pa.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has cleared the ARTIS […]

Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board

Dr. Geall Joins the Company’s World-class Scientific Advisors in Cardiology, Vaccine Development and Human Genetics   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of Andrew Geall, […]

Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

– APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin […]